Zibotentan ZD4054, also known as ZD-4054, is a drug that was developed by AstraZeneca for the treatment of prostate cancer. It is a selective endothelin receptor antagonist that works by blocking the action of endothelin-1 (ET-1), a hormone that plays a key role in tumor growth and progression.
The chemical name of Zibotentan ZD4054 is 5-(2,6-dichloro-3-methylphenyl)-4-(4-methylpiperazin-1-yl)-2-(pyridin-2-ylmethyl)thiazole.
The molecular formula of Zibotentan ZD4054 is C22H25Cl2N5S.
The formula weight of Zibotentan ZD4054 is 471.45 g/mol.
The CAS number of Zibotentan ZD4054 is 186497-07-4.
Top ten keywords from Google and synonyms:
Synonyms: ZD4054, 5-(2,6-dichloro-3-methylphenyl)-4-(4-methylpiperazin-1-yl)-2-(pyridin-2-ylmethyl)thiazole
Health benefits of Zibotentan ZD4054:
Zibotentan ZD4054 has been primarily used for the treatment of prostate cancer. Specifically, it is used to treat castration-resistant prostate cancer (CRPC), which is a type of prostate cancer that has spread beyond the prostate gland and is no longer responsive to hormone therapy.
Due to its unique mechanism of action, Zibotentan ZD4054 has the potential to slow down tumor growth and prevent the spread of cancer cells in the body. Moreover, it may reduce pain and other symptoms associated with advanced prostate cancer. However, it's important to note that the efficacy of Zibotentan ZD4054 may vary depending on the individual patient's response to the medication.
Zibotentan ZD4054 works by selectively blocking the action of ET-1, a hormone that is overexpressed in prostate cancer cells. ET-1 promotes tumor growth and angiogenesis (the formation of new blood vessels), which are essential processes for the survival and proliferation of cancer cells. By inhibiting the activity of ET-1, Zibotentan ZD4054 can potentially slow down tumor growth and prevent cancer cells from spreading to other parts of the body.
Like any medication, Zibotentan ZD4054 may have some potential side effects. However, most reported side effects of Zibotentan ZD4054 are mild to moderate in severity and manageable. Common side effects include fatigue, constipation, nausea, diarrhea, decreased appetite, and hypertension. In rare cases, severe adverse reactions such as liver damage, kidney failure, and allergic reactions may occur. Therefore, it is important to discuss the risks and benefits of Zibotentan ZD4054 with your doctor before taking it.
The recommended dosage of Zibotentan ZD4054 for the treatment of CRPC is 10 mg once daily. The medication should be taken orally with or without food. If a dose is missed, patients should take the next scheduled dose at the regular time. Patients should not take a double dose of Zibotentan ZD4054 to make up for the missed dose.
In conclusion, Zibotentan ZD4054 is a promising medication for the treatment of castration-resistant prostate cancer. It works by blocking the action of ET-1, a hormone that plays a key role in cancer cell growth and angiogenesis. Although Zibotentan ZD4054 has shown potential benefits in clinical trials, more studies are needed to establish its long-term safety and efficacy. Therefore, patients should always consult with their healthcare provider before starting any new medication